Rafael Holdings, Inc.
520 Broad Street
Newark, NJ 07102
United States
212 658 1450
https://www.rafaelholdings.com
版塊: Real Estate
行業: Real Estate Services
全職員工: 13
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Howard S. Jonas | Founder & Executive Chairman | 40k | 無 | 1956 |
| Mr. William Conkling | CEO & President | 751.95k | 無 | 1972 |
| Mr. David A. Polinsky Esq. | Chief Financial Officer | 363.3k | 無 | 1972 |
| Ms. Barbara A. Ryan | Investor Relations Officer | 無 | 無 | 1960 |
| Mr. Gus Kodersha | Chief Technical Operations Officer | 無 | 無 | 無 |
| Dr. Rick Ewing | Head of Drug Discovery | 無 | 無 | 無 |
| Dr. John Mayer Goldberg M.D. | Chief Medical Officer | 無 | 無 | 1973 |
| Ms. Joyce J. Mason Esq. | Corporate Secretary | 無 | 無 | 1959 |
描述
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
公司管治
截至 2024年5月1日 止，Rafael Holdings, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：10；董事會：9；股東權利：10；現金賠償：9。
